Cover Image
市場調查報告書

神經性疼痛:開發中產品分析

Neuropathic Pain - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232786
出版日期 內容資訊 英文 488 Pages
訂單完成後即時交付
價格
Back to Top
神經性疼痛:開發中產品分析 Neuropathic Pain - Pipeline Review, H2 2017
出版日期: 2017年12月29日 內容資訊: 英文 488 Pages
簡介

神經性疼痛,或是神經痛是指感覺系統收到的狀態,一般伴隨組織障礙。神經線維損傷的話會發生異常信號。神經性疼痛與其他疾病一起發生。症侯從電擊痛到沒有感覺。 雖然引起疼痛的原因有好幾個,但是沒有特定的原因。身體的外傷、腎臟病、酒精成癮(酒精中毒)、感染疾病、壓力等也與疼痛的症狀相連。治療以藥物療法和心理治療來緩和症狀。

本報告提供神經性疼痛的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

神經性疼痛概要

治療藥的開發

神經性疼痛:企業開發中的治療藥

神經性疼痛:大學/機關研究中的治療藥

神經性疼痛:開發中產品概況

神經性疼痛:企業開發中的產品

神經性疼痛:大學/機關研究中的產品

神經性疼痛的治療藥開發作的企業

神經性疼痛:治療藥的評估

藥物簡介

神經性疼痛:暫停中的計劃

神經性疼痛:開發中止的產品

神經性疼痛:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9966IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain - Pipeline Review, H2 2017, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.

Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 6, 24, 29, 1, 114, 27 and 4 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 37 and 1 molecules, respectively.

Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Neuropathic Pain - Overview
  • Neuropathic Pain - Therapeutics Development
  • Neuropathic Pain - Therapeutics Assessment
  • Neuropathic Pain - Companies Involved in Therapeutics Development
  • Neuropathic Pain - Drug Profiles
  • Neuropathic Pain - Dormant Projects
  • Neuropathic Pain - Discontinued Products
  • Neuropathic Pain - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Neuropathic Pain, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..7), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..8), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..9), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..10), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..11), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Neuropathic Pain - Pipeline by 2-BBB Medicines BV, H2 2017
  • Neuropathic Pain - Pipeline by AbbVie Inc, H2 2017
  • Neuropathic Pain - Pipeline by Abide Therapeutics Inc, H2 2017
  • Neuropathic Pain - Pipeline by Acadia Pharmaceuticals Inc, H2 2017
  • Neuropathic Pain - Pipeline by Achelios Therapeutics Inc, H2 2017
  • Neuropathic Pain - Pipeline by Affectis Pharmaceuticals AG, H2 2017
  • Neuropathic Pain - Pipeline by AnaBios Corp, H2 2017
  • Neuropathic Pain - Pipeline by Anavex Life Sciences Corp, H2 2017
  • Neuropathic Pain - Pipeline by AngioChem Inc, H2 2017
  • Neuropathic Pain - Pipeline by Aptinyx Inc, H2 2017
  • Neuropathic Pain - Pipeline by Arena Pharmaceuticals Inc, H2 2017
  • Neuropathic Pain - Pipeline by Astellas Pharma Inc, H2 2017
  • Neuropathic Pain - Pipeline by AstraZeneca Plc, H2 2017
  • Neuropathic Pain - Pipeline by Aucta Pharmaceuticals LLC, H2 2017
  • Neuropathic Pain - Pipeline by BCI Pharma, H2 2017
  • Neuropathic Pain - Pipeline by BCN Peptides SA, H2 2017
  • Neuropathic Pain - Pipeline by Biogen Inc, H2 2017
  • Neuropathic Pain - Pipeline by Bionomics Ltd, H2 2017
  • Neuropathic Pain - Pipeline by Bristol-Myers Squibb Co, H2 2017
  • Neuropathic Pain - Pipeline by Can-Fite BioPharma Ltd, H2 2017
  • Neuropathic Pain - Pipeline by Cara Therapeutics Inc, H2 2017
  • Neuropathic Pain - Pipeline by Celgene Corp, H2 2017
  • Neuropathic Pain - Pipeline by Centrexion Therapeutics Corp, H2 2017
  • Neuropathic Pain - Pipeline by Cerecor Inc, H2 2017
  • Neuropathic Pain - Pipeline by Chromocell Corp, H2 2017
  • Neuropathic Pain - Pipeline by Circuit Therapeutics Inc, H2 2017
  • Neuropathic Pain - Pipeline by Colby Pharmaceutical Co, H2 2017
  • Neuropathic Pain - Pipeline by ConSynance Therapeutics Inc, H2 2017
  • Neuropathic Pain - Pipeline by ContraVir Pharmaceuticals Inc, H2 2017
  • Neuropathic Pain - Pipeline by Crinetics Pharmaceuticals Inc, H2 2017
  • Neuropathic Pain - Pipeline by Cytogel Pharma LLC, H2 2017
  • Neuropathic Pain - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
  • Neuropathic Pain - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
  • Neuropathic Pain - Pipeline by Develco Pharma Schweiz AG, H2 2017
  • Neuropathic Pain - Pipeline by Dompe Farmaceutici SpA, H2 2017
  • Neuropathic Pain - Pipeline by Eisai Co Ltd, H2 2017

List of Figures

  • Number of Products under Development for Neuropathic Pain, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017 1
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top